Today: 11 June 2026
Palantir (PLTR) Edges Lower on Nov. 7 as Insider Sale Surfaces—Analysts Lift Targets After Blowout Q3
7 November 2025
3 mins read

Palantir (PLTR) Edges Lower on Nov. 7 as Insider Sale Surfaces—Analysts Lift Targets After Blowout Q3

  • PLTR shares are modestly lower intraday as the recent AI-led rally cools; macro jitters and valuation debate remain in focus.
  • Director Alexander “Alex” Moore disclosed a Form 4 sale of ~20,000 shares (~$4.09M) executed Nov. 3 under a pre‑set 10b5‑1 plan; he still holds ~1.23M shares after the trade. SEC
  • Institutional flow: SouthState Corp reported boosting its PLTR position in the latest filing cycle.
  • Street reaction remains constructive: Bank of America raised its PLTR price target to $255 post‑earnings; other firms stay positive but caution on valuation.
  • Fundamentals still strong: Q3 revenue grew 63% Y/Y to $1.181B; U.S. commercial revenue +121% Y/Y; Q4 sales guided to $1.327–$1.331B.

Today’s market action: valuation hangover meets broader AI wobble

PLTR is easing on Friday, extending a mid‑week pullback that followed record Q3 results. The move comes alongside a broader AI stock wobble and a “risk‑off” tone across U.S. equities, as investors reassess premium multiples in the AI trade. Reuters+1

Fresh filing: Director Alex Moore’s 10b5‑1 sale

A new SEC Form 4 filed late Wednesday shows Director Alexander D. Moore sold a total of ~20,000 Class A shares on Nov. 3 across several price tranches ($202.63–$206.60 weighted‑average ranges). The filing explicitly notes sales were executed under a Rule 10b5‑1 plan adopted Nov. 22, 2024. After the transactions, Moore’s direct holdings total ~1,232,978 shares. Insider sales executed through 10b5‑1 plans are typically pre‑scheduled and do not necessarily signal a change in outlook.

Institutional flows: SouthState adds to PLTR

SouthState Corp disclosed an increase in its PLTR stake in the most recent reporting period, according to a MarketBeat summary of 13F data published today. While the position is small in dollar terms relative to mega‑holders, it adds to the picture of continued institutional participation in the name.

Street still turning the dial up

Following the company’s Q3 beat and raised outlook this week, Bank of America took its price target to $255 and reiterated Buy, citing durable AI monetization and Palantir’s differentiated go‑to‑market motion (AIP bootcamps, forward‑deployed engineers, and ontology‑first deployments). Other bullish notes have maintained high‑$100s to low‑$200s targets, though several analysts continue to flag valuation risk near record highs.

Earnings recap: momentum intact

On Nov. 3, Palantir reported Q3 2025 revenue of $1.181B (+63% Y/Y) and adjusted EPS of $0.21, and guided Q4 revenue to $1.327–$1.331B, lifting full‑year expectations. The company also highlighted U.S. commercial revenue up 121% Y/Y—a metric many on the Street view as the clearest proof of non‑government AI adoption at scale.

Strategic context: contracts and catalysts to watch

  • Defense footprint: Over the summer, the U.S. Army consolidated dozens of agreements into an enterprise deal with optionality up to $10B over 10 years, underscoring Palantir’s role in the Army’s data/AI stack. While not a guaranteed purchase amount, the umbrella structure streamlines future call‑offs.
  • Allied adoption: NATO moved to acquire an AI‑enabled Maven Smart System variant earlier this year, accelerating fieldable decision‑support tooling across the alliance.
  • AI partner ecosystem: A fresh Nvidia–Palantir collaboration is aimed at speeding operational AI in complex domains like logistics—an area investors are monitoring for incremental commercial wins.

Why shares are softer today despite strong prints

  1. Macro/AI multiple reset: The market is digesting a year of outsized gains in AI leaders; pullbacks can follow even stellar reports.
  2. Valuation debate: Some coverage highlights extended EV/revenue and P/E multiples versus software peers. Post‑print commentary this week repeatedly flagged this risk even as PTs moved higher.
  3. Headline sensitivity:Insider sale headlines can weigh in the short run even when pre‑planned under 10b5‑1. The underlying SEC filing indicates a scheduled plan and sizeable remaining ownership.

What could move PLTR next

  • Q4 execution vs. lofty guide ($1.327–$1.331B): book‑to‑bill, U.S. commercial adds, and AI platform expansion are the focus.
  • Large‑deal cadence under the Army enterprise vehicle and other federal frameworks.
  • Commercial AI proof points (AIP deployments, bootcamp conversions, and Nvidia‑assisted use cases) that could support premium multiples—or expose them to compression.

The bottom line

On Nov. 7, 2025, Palantir’s stock is drifting lower as part of a broader AI cooldown and sensitivity to headlines, even as fundamentals and Street targets trend higher post‑Q3. For investors, the tension between surging execution and premium valuation remains the defining narrative into year‑end.

Disclosure: This article is for informational purposes only and does not constitute investment advice. Always do your own research.

A technology and finance expert writing for TS2.tech. He analyzes developments in satellites, telecommunications, and artificial intelligence, with a focus on their impact on global markets. Author of industry reports and market commentary, often cited in tech and business media. Passionate about innovation and the digital economy.

Stock Market Today

  • Sigma Healthcare's Valuation Reassessed After Recent Share Price Declines
    June 11, 2026, 4:09 PM EDT. Sigma Healthcare (ASX:SIG) shares have declined 7.6% over the past week and 15.5% over the past year but exhibit strong long-term gains with a 231.7% return over three years. The stock currently trades at A$2.69, slightly below Simply Wall St's discounted cash flow (DCF) valuation of A$2.81 per share, indicating it is roughly fairly valued with a 4.1% discount. Despite short-term price weakness, Sigma Healthcare scores 2 out of 6 on valuation metrics, suggesting mixed signals on undervaluation. Its free cash flow is projected to increase substantially through 2028, supporting the fair value estimate. Investors are balancing recent price softness with long-term fundamentals amid ongoing reassessments of risk and return in Australia's healthcare supply chain sector.

Latest articles

Coeur Mining Climbs as S&P MidCap 400 Inclusion Approaches, Silver Stocks Gain

Coeur Mining Climbs as S&P MidCap 400 Inclusion Approaches, Silver Stocks Gain

11 June 2026
Coeur Mining surged 5.2% to $16.205 on heavy volume as investors positioned ahead of its S&P MidCap 400 addition effective June 22, following recent acquisitions and a sector-wide rally in precious-metals stocks; the company’s market cap hit $16.76 billion, with index inclusion and recent financial results drawing institutional attention.
Trump Media drops Truth Social spin-off, DJT holders turn to $6 bln TAE merger

Trump Media drops Truth Social spin-off, DJT holders turn to $6 bln TAE merger

11 June 2026
Trump Media, TAE Technologies and Texas Ventures Acquisition III have scrapped plans to spin off Truth Social and other media assets, keeping them within Trump Media as it pursues a merger with TAE; DJT shares traded at $8.03 Thursday after falling over 38% this year, with the next key event being the merger filing process and SEC registration.
Interstellar Comet 3I/ATLAS: A Visitor from Beyond the Solar System
Previous Story

Comet 3I/ATLAS today (6 Nov 2025): China’s Mars orbiter snaps new photos as the interstellar visitor turns bluer and shows puzzling acceleration

Bubble or Boom? Magnificent Seven Stocks Face Critical Earnings Showdown
Next Story

Alphabet (GOOGL) Stock Today, Nov 7, 2025: Shares Slip ~2.6% as YouTube TV–Disney Blackout Persists; DOJ Clears $32B Wiz Deal

Go toTop